HC Wainwright restated their neutral rating on shares of RAPT Therapeutics (NASDAQ:RAPT - Free Report) in a research report sent to investors on Wednesday morning, Benzinga reports.
Other research analysts have also issued research reports about the company. Evercore ISI assumed coverage on RAPT Therapeutics in a research report on Friday, February 16th. They set an outperform rating for the company. SVB Leerink lowered RAPT Therapeutics from an outperform rating to a market perform rating and reduced their price objective for the company from $42.00 to $10.00 in a research report on Wednesday, February 21st. Barclays reduced their price objective on RAPT Therapeutics from $35.00 to $13.00 and set an overweight rating for the company in a research report on Wednesday, February 21st. Cantor Fitzgerald lowered RAPT Therapeutics from an overweight rating to a neutral rating in a research report on Tuesday, February 20th. Finally, UBS Group lowered RAPT Therapeutics from a buy rating to a neutral rating and reduced their price objective for the company from $61.00 to $10.00 in a research report on Thursday, February 22nd. Six investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the company's stock. According to data from MarketBeat.com, RAPT Therapeutics currently has an average rating of Moderate Buy and an average target price of $25.67.
Get Our Latest Stock Report on RAPT Therapeutics
RAPT Therapeutics Stock Up 6.9 %
Shares of RAPT traded up $0.58 during mid-day trading on Wednesday, hitting $9.02. The stock had a trading volume of 920,029 shares, compared to its average volume of 1,208,441. The company has a market cap of $313.90 million, a PE ratio of -2.97 and a beta of 0.47. The company's fifty day simple moving average is $13.34 and its two-hundred day simple moving average is $16.18. RAPT Therapeutics has a fifty-two week low of $6.86 and a fifty-two week high of $27.35.
RAPT Therapeutics (NASDAQ:RAPT - Get Free Report) last issued its earnings results on Thursday, March 7th. The company reported ($0.80) EPS for the quarter, topping the consensus estimate of ($0.85) by $0.05. Equities analysts expect that RAPT Therapeutics will post -3.19 earnings per share for the current year.
Institutional Inflows and Outflows
A number of institutional investors have recently added to or reduced their stakes in RAPT. Swiss National Bank raised its stake in shares of RAPT Therapeutics by 9.6% in the 3rd quarter. Swiss National Bank now owns 49,100 shares of the company's stock worth $816,000 after buying an additional 4,300 shares in the last quarter. FMR LLC raised its stake in shares of RAPT Therapeutics by 7.4% in the 3rd quarter. FMR LLC now owns 4,499,293 shares of the company's stock worth $74,778,000 after buying an additional 308,804 shares in the last quarter. China Universal Asset Management Co. Ltd. raised its stake in shares of RAPT Therapeutics by 347.8% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 3,981 shares of the company's stock worth $99,000 after buying an additional 3,092 shares in the last quarter. Braidwell LP raised its stake in shares of RAPT Therapeutics by 10.0% in the 3rd quarter. Braidwell LP now owns 1,082,512 shares of the company's stock worth $17,991,000 after buying an additional 98,112 shares in the last quarter. Finally, TD Asset Management Inc raised its stake in shares of RAPT Therapeutics by 67.4% in the 3rd quarter. TD Asset Management Inc now owns 153,618 shares of the company's stock worth $2,553,000 after buying an additional 61,831 shares in the last quarter. Institutional investors and hedge funds own 99.09% of the company's stock.
About RAPT Therapeutics
(
Get Free Report)
RAPT Therapeutics, Inc, a clinical-stage immunology-based biopharmaceutical company, focuses on discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. The company's lead inflammation drug candidate is zelnecirnon (RPT193), a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues.
See Also
Before you consider RAPT Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and RAPT Therapeutics wasn't on the list.
While RAPT Therapeutics currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
